Bayhill Therapeutics, Inc. Founder Lawrence Steinman, M.D. Recognized for Leadership in Multiple Sclerosis
3/16/2009 10:01:06 AM
SAN MATEO, Calif.--(BUSINESS WIRE)--Bayhill Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging its proprietary BHT-DNA™ platform to develop novel and targeted autoimmune disease treatments, today announced that Lawrence Steinman M.D., Professor of Neurology, Pediatrics and Genetics at Stanford University and Founder, Director and Scientific Advisory Board Chairman of Bayhill Therapeutics, has been awarded an endowed chair at Stanford as the George A. Zimmerman Professor. Dr. Steinman is the inaugural holder of the chair, funded to support multiple sclerosis (MS) research. A member of Stanford’s faculty since 1980, Dr. Steinman has focused his 30-year career on translational and clinical research in MS.
comments powered by